Compass Therapeutics (CMPX) Non Operating Income (2019 - 2020)
Compass Therapeutics (CMPX) reported Non Operating Income of -$1.2 million for Q3 2020, down 202.99% on a YoY basis from $1.2 million in Q4 2019, and down 18.42% sequentially from -$1.0 million in Q2 2020.
Compass Therapeutics (CMPX) Non Operating Income (2019 - 2020) Analysis & Trends
Compass Therapeutics (CMPX) has 2 years of Non Operating Income data on file, last reported at -$1.2 million in Q3 2020.
- For the quarter ending Q3 2020, Non Operating Income fell 202.99% year-over-year to -$1.2 million; the trailing twelve-month figure through Sep 2020 stood at -$2.9 million (changed N/A YoY), and the FY2020 full-year result was -$1.7 million, down 175.54% from the prior year.
- Non Operating Income fell to -$1.2 million in Q3 2020, from -$1.0 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of -$258000.0 in Q2 2019 to a low of -$1.2 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Compass Therapeutics | 395.17 Mn | 200.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -1.22 Mn |
| Jun 30, 2020 | -1.03 Mn |
| Sep 30, 2019 | -401,000.00 |
| Jun 30, 2019 | -258,000.00 |